ARQT News and Press, Arcutis Biotherapeutics Inc. From 02/28/23

Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growth Secured expanded commercial payer coverage for ZORYVE in plaque psoriasis with the second of the top three pharmacy be...

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United States If approved, roflumilast foam would be the first topical drug for seborrheic dermatitis with a new mechanism of action in over two decades In a pivotal Phase 3 trial, 80% ...

Summary The market has discounted momentum around Arcutis' Zoryve label. This looks overdone and investors appear to have overlooked the additional data points surrounding the segment. We are looking for positive numbers in the company's upcoming FY22 earnings. Alas, we are ente...

Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ET Arcutis management will also participate in the Cowen 43 rd Annual Healthcare Conference in March WESTLAKE VILLAGE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeuti...

Cowen, which has an outperform rating on Arcutis Biotherapeutics ( NASDAQ: ARQT ), is recommending that investors add to their positions as the stock is trading at a discounted price amid positive feedback on the company's recently launched plaque psoriasis cream Zoryve (roflumilast). ...

During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks) Efficacy was consistent over time across all endpoint...

Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque psoriasis If approved, ZORYVE would be the first steroid-free topical phosphodiesterase-4 (PDE4) ...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) announced Monday that its investigational topical formulation roflumilast cream achieved the primary endpoint in the second pivotal Phase 3 trial for atopic dermatitis (AD). Arcutis ( ARQT ) fell ~5% shortly after the company shares resumed...

Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in November For the primary endpoint, 28.9% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success com...

ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areata Proprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver drug deep into the skin to the base of the hair follicle where key alopecia areata inflammati...